- Home
- QLYS vs LEGN Comparison
QLYS vs LEGN Comparison
Compare QLYS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | LEGN |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QLYS | LEGN |
|---|---|---|
| Price | $129.27 | $21.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $139.43 | $69.58 |
| AVG Volume (30 Days) | 418.3K | ★ 2.5M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.91 | N/A |
| EPS | ★ 5.16 | N/A |
| Revenue | $653,034,000.00 | ★ $909,045,000.00 |
| Revenue This Year | $12.00 | $68.52 |
| Revenue Next Year | $7.68 | $48.63 |
| P/E Ratio | $25.40 | ★ N/A |
| Revenue Growth | 10.13 | ★ 74.75 |
| 52 Week Low | $112.61 | $20.26 |
| 52 Week High | $155.47 | $45.30 |
Technical Indicators
Market Signals| Indicator | QLYS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 32.98 |
| Support Level | $129.05 | $21.19 |
| Resistance Level | $140.74 | $22.07 |
| Average True Range (ATR) | 3.45 | 0.77 |
| MACD | -1.71 | 0.12 |
| Stochastic Oscillator | 1.66 | 30.20 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.